Novel treatments that have shown activity against AML with mtNPM1 include arsenic trioxide, which causes degradation of NPM1c, or selinexor the inhibitor of exportin-1 (gene product of XPO1 gene) which blocks cytoplasmic dislocation of NPM1c [13, 14]. The gene discussed is XPO1; the disease is acute myeloid leukemia.